<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36575589</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2576-2095</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Animal models and experimental medicine</Title><ISOAbbreviation>Animal Model Exp Med</ISOAbbreviation></Journal><ArticleTitle>Neutralizing peripheral circulating IL1&#x3b2; slows the progression of ALS in a lentivirus-infected OPTN<sup>E478G</sup> mouse model.</ArticleTitle><Pagination><StartPage>18</StartPage><EndPage>25</EndPage><MedlinePgn>18-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ame2.12297</ELocationID><Abstract><AbstractText Label="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is irreversible and fatal within 3-5&#x2009;years, with limited options for treatment. It is imperative to develop a symptom-based treatment that may increase the survival of ALS patients and improve their quality of life. Inflammation status, especially elevated interleukin 1&#x3b2; (IL1&#x3b2;), has been reported to play a critical role in ALS progression. Our study determined that neutralizing circulating IL1&#x3b2; slows down the progression of ALS in an ALS mouse model.</AbstractText><AbstractText Label="METHODS">The ALS mouse model was developed by microinjection of lentivirus-carrying OPTN<sup>E478G</sup> (optineurin, a mutation from ALS patients) into the intra-motor cortex of mice. Peripheral circulating IL1&#x3b2; was neutralized by injecting anti-IL1&#x3b2; antibody into the tail vein. Enzyme-linked immunosorbent assay (ELISA) and real-time polymerase chain reaction (RT-PCR) were carried out to determine the protein and gene expression levels of IL1&#x3b2;. TUNEL assay was used to assess the neural cell death. Immunofluorescent staining of MAP2 and CASP3 was accomplished to evaluate neuronal cell apoptosis. Glial fibrillary acidic protein staining was performed to analyze the number of astrocytes. Rotarod test, grip strength test, balance beam test, and footprint test were conducted to assess the locomotive function after anti-IL1&#x3b2; treatment.</AbstractText><AbstractText Label="RESULTS">The model revealed that neuroinflammation contributes to ALS progression. ALS mice exhibited elevated neuroinflammation and IL1&#x3b2; secretion. After anti-IL1&#x3b2; treatment, ALS mice revealed decreased neural cell death and astrogliosis and gained improved muscle strength and motor ability.</AbstractText><AbstractText Label="CONCLUSIONS">Blocking IL1&#x3b2; is a promising strategy to slow down the progression of ALS.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Animal Models and Experimental Medicine published by John Wiley &amp; Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Wen-Bao</ForeName><Initials>WB</Initials><AffiliationInfo><Affiliation>Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Zhi-Lin</ForeName><Initials>ZL</Initials><AffiliationInfo><Affiliation>Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Chun-Gu</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zheng-Zhao</ForeName><Initials>ZZ</Initials><Identifier Source="ORCID">0000-0003-0659-2775</Identifier><AffiliationInfo><Affiliation>Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Animal Model Exp Med</MedlineTA><NlmUniqueID>101726292</NlmUniqueID><ISSNLinking>2576-2095</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501288">Optn protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016086" MajorTopicYN="N">Lentivirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">interleukin 1&#x3b2;</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">optineurin</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>28</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36575589</ArticleId><ArticleId IdType="pmc">PMC9986221</ArticleId><ArticleId IdType="doi">10.1002/ame2.12297</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197&#x2010;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2010;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137(5):715&#x2010;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1&#x2010;induced IL&#x2010;1beta accelerates ALS pathogenesis. Proc Natl Acad Sci U S A. 2010;107(29):13046&#x2010;13050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919927</ArticleId><ArticleId IdType="pubmed">20616033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravnik&#x2010;Glavac M, Gori&#x10d;ar K, Vogrinc D, et al. Genetic variability of inflammation and oxidative stress genes affects onset, progression of the disease and survival of patients with amyotrophic lateral sclerosis. Genes (Basel). 2022;13(5):757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9140599</ArticleId><ArticleId IdType="pubmed">35627142</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Li H, Hong C, et al. ALS&#x2010;associated E478G mutation in human OPTN (Optineurin) promotes inflammation and induces neuronal cell death. Front Immunol. 2018;9:2647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251386</ArticleId><ArticleId IdType="pubmed">30519240</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Chen P, Gao H, et al. Ubiquitylation of autophagy receptor optineurin by HACE1 activates selective autophagy for tumor suppression. Cancer Cell. 2014;26(1):106&#x2010;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4166492</ArticleId><ArticleId IdType="pubmed">25026213</ArticleId></ArticleIdList></Reference><Reference><Citation>Barez&#x2010;Lopez S, Bosch&#x2010;Garc&#xed;a D, G&#xf3;mez&#x2010;Andr&#xe9;s D, et al. Abnormal motor phenotype at adult stages in mice lacking type 2 deiodinase. PLoS ONE. 2014;9(8):e103857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4118963</ArticleId><ArticleId IdType="pubmed">25083788</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayabal S, Ljungberg L, Erwes T, et al. Rapid onset of motor deficits in a mouse model of spinocerebellar ataxia type 6 precedes late cerebellar degeneration. eNeuro. 2015;2(6):ENEURO.0094&#x2010;15.2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4697081</ArticleId><ArticleId IdType="pubmed">26730403</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinai L, Ivakine EA, Lam E, et al. Disruption of Src is associated with phenotypes related to Williams&#x2010;Beuren syndrome and altered cellular localization of TFII&#x2010;I. eNeuro. 2015;2(2):ENEURO.0016&#x2010;14.2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4596087</ArticleId><ArticleId IdType="pubmed">26464974</ArticleId></ArticleIdList></Reference><Reference><Citation>Watthanasurorot A, Jiravanichpaisal P, S&#xf6;derh&#xe4;ll K, S&#xf6;derh&#xe4;ll I. A calreticulin/gC1qR complex prevents cells from dying: a conserved mechanism from arthropods to humans. J Mol Cell Biol. 2013;5(2):120&#x2010;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">23378602</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Chen X, Lin W, et al. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial&#x2010;dependent apoptosis. Int J Oncol. 2013;42(3):971&#x2010;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">23338043</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Meer JW, Simon A. Blocking IL&#x2010;1beta to slow down progression of ALS? Proc Natl Acad Sci U S A. 2010;107(29):12741&#x2010;12742.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919971</ArticleId><ArticleId IdType="pubmed">20624959</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465(7295):223&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Hooten KG, et al. Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol. 2017;74(6):677&#x2010;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin XY, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta&#x2010;analysis study. Sci Rep. 2017;7(1):9094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhart J, Smith AJ, Kuzmin&#x2010;Nichols N, et al. Humoral factors in ALS patients during disease progression. J Neuroinflammation. 2015;12:127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4487852</ArticleId><ArticleId IdType="pubmed">26126965</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks WA. Blood&#x2010;brain barrier transport of cytokines: a mechanism for neuropathology. Curr Pharm des. 2005;11(8):973&#x2010;984.</Citation><ArticleIdList><ArticleId IdType="pubmed">15777248</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Xue R, Hu R. The neuroprotective effect and action mechanism of polyphenols in diabetes mellitus&#x2010;related cognitive dysfunction. Eur J Nutr. 2020;59(4):1295&#x2010;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">31598747</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G, Franklin KBJ, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. 2nd ed. Academic Press; 2001.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>